{"entity":{"id":"aurelia","kind":"trial","name":"AURELIA","aka":["MO22224"],"tldr":"AURELIA showed that adding bevacizumab to single-drug chemotherapy for ovarian cancer that has stopped responding to platinum doubled the time before the cancer grew again, from 3.4 to 6.7 months, and more than doubled the response rate, though it did not clearly lengthen life.","summary":"AURELIA was an open-label phase 3 trial in 361 women with platinum-resistant ovarian cancer randomised to the investigator's choice of weekly paclitaxel, pegylated liposomal doxorubicin or topotecan, alone or with bevacizumab. The primary endpoint was progression-free survival.\n\nMedian progression-free survival was 6.7 months with bevacizumab against 3.4 months with chemotherapy alone (hazard ratio 0.48), the response rate 27.3 against 11.8 percent and median overall survival 16.6 against 13.3 months (hazard ratio 0.85, not significant). Hypertension and proteinuria were more common with bevacizumab and gastrointestinal perforation occurred in 2.2 percent. The trial led to approval of bevacizumab with chemotherapy for platinum-resistant disease in the United States in November 2014, which is how the corpus's platinum-resistant ovarian cancer page cites it.","status":"positive","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00976911","url":"https://clinicaltrials.gov/study/NCT00976911"}],"tags":["soc-trials"],"related":[],"cancers":["platinum-resistant-ovarian-cancer","ovarian"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["bevacizumab","paclitaxel","pegylated-liposomal-doxorubicin","topotecan"],"companies":["roche-genentech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00976911","phase":"3","setting":"Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer after no more than two prior regimens: the investigator's single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin or topotecan) with or without bevacizumab, with progression-free survival as the primary endpoint","sponsor":"Hoffmann-La Roche","result":"Median progression-free survival 6.7 months with bevacizumab plus chemotherapy against 3.4 months with chemotherapy alone (hazard ratio 0.48, p < 0.001); response rate 27.3 against 11.8 percent; overall survival not significantly different (16.6 against 13.3 months).","yearReported":2014,"enrolled":361,"enrolledBasis":"registry","outcomes":[{"endpoint":"Progression-free survival","primary":true,"unit":"months","arms":[{"name":"Bevacizumab + single-agent chemotherapy","value":6.7},{"name":"Single-agent chemotherapy","value":3.4}],"hr":0.48,"ci":[0.38,0.6],"p":"<0.001","source":"https://doi.org/10.1200/JCO.2013.51.4489"},{"endpoint":"Progression-free survival (registry results, November 2011 cut-off)","unit":"months","arms":[{"name":"Bevacizumab + single-agent chemotherapy","value":6.8,"note":"95% CI 5.62 to 7.79"},{"name":"Single-agent chemotherapy","value":3.4,"note":"95% CI 2.10 to 3.75"}],"hr":0.46,"ci":[0.366,0.577],"p":"<0.0001","source":"https://clinicaltrials.gov/study/NCT00976911?tab=results"},{"endpoint":"Objective response rate (RECIST)","unit":"%","arms":[{"name":"Bevacizumab + single-agent chemotherapy","value":27.3},{"name":"Single-agent chemotherapy","value":11.8}],"p":"0.001","source":"https://doi.org/10.1200/JCO.2013.51.4489"},{"endpoint":"Overall survival","unit":"months","arms":[{"name":"Bevacizumab + single-agent chemotherapy","value":16.6},{"name":"Single-agent chemotherapy","value":13.3}],"hr":0.85,"ci":[0.66,1.08],"p":"0.174","source":"https://doi.org/10.1200/JCO.2013.51.4489"},{"endpoint":"Gastrointestinal perforation","unit":"%","arms":[{"name":"Bevacizumab + single-agent chemotherapy","value":2.2}],"source":"https://doi.org/10.1200/JCO.2013.51.4489"}]},"route":"/trials/aurelia/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"platinum-resistant-ovarian-cancer","kind":"cancer","name":"Platinum-resistant ovarian cancer","route":"/cancers/platinum-resistant-ovarian-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pegylated-liposomal-doxorubicin","kind":"drug","name":"Pegylated liposomal doxorubicin","route":"/drugs/pegylated-liposomal-doxorubicin/"},{"id":"topotecan","kind":"drug","name":"Topotecan","route":"/drugs/topotecan/"}],"company":[{"id":"roche-genentech","kind":"company","name":"Roche / Genentech","route":"/companies/roche-genentech/"}],"paper":[{"id":"paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014","kind":"paper","name":"AURELIA: bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer","route":"/key-papers/paper-aurelia-bevacizumab-platinum-resistant-ovarian-pujade-lauraine-jco-2014/"}]}}